Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers

Sukeepaisarnjaroen W; Pham T; Tanwandee T; Nazareth S; Galhenage S; Mollison L; Totten L; Wigg A; Altus R; Colman A; Morales B; Mason S; Jones T; Leembruggen N; Fragomelli V; Sendall C; Guan R; Sutedja D; Tan SS; Dan YY; Lee YM; Luman W; Teo EK; Than YM; Piratvisuth T; Lim SG

doi:10.3748/wjg.v21.i28.8660

Fulltext

Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers

Sukeepaisarnjaroen W ¹ , Pham T ¹ , Tanwandee T ¹ , Nazareth S ¹ , Galhenage S ¹ , Mollison L ¹ Show all authors , Totten L ¹ , Wigg A ¹ , Altus R ¹ , Colman A ¹ , Morales B ¹ , Mason S ¹ , Jones T ¹ , Leembruggen N ¹ , Fragomelli V ¹ , Sendall C ¹ , Guan R ¹ , Sutedja D ¹ , Tan SS ¹ , Dan YY ¹ , Lee YM ¹ , Luman W ¹ , Teo EK ¹ , Than YM ¹ , Piratvisuth T ¹ , Lim SG ¹

Affiliations

¹ Wattana Sukeepaisarnjaroen, Srinagarind Hospital, Chiangmai 40002, Khon Kaen, Thailand

World J Gastroenterol, 2015 Jul 28;21(28):8660-9.

PMID: 26229408 DOI: 10.3748/wjg.v21.i28.8660

Abstract

To examined the efficacy and safety of treatment with boceprevir, PEGylated-interferon and ribavirin (PR) in hepatitis C virus genotype 1 (HCVGT1) PR treatment-failures in Asia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.